Modulation of Gut-Specific Mechanisms by Chronic Δ 9 -Tetrahydrocannabinol Administration in Male Rhesus Macaques Infected with Simian Immunodeficiency Virus: A Systems Biology Analysis
Restricted accessResearch articleFirst published online June, 2014
Modulation of Gut-Specific Mechanisms by Chronic Δ 9 -Tetrahydrocannabinol Administration in Male Rhesus Macaques Infected with Simian Immunodeficiency Virus: A Systems Biology Analysis
Our studies have demonstrated that chronic Δ9-tetrahydrocannabinol (THC) administration results in a generalized attenuation of viral load and tissue inflammation in simian immunodeficiency virus (SIV)-infected male rhesus macaques. Gut-associated lymphoid tissue is an important site for HIV replication and inflammation that can impact disease progression. We used a systems approach to examine the duodenal immune environment in 4- to 6-year-old male rhesus monkeys inoculated intravenously with SIVMAC251 after 17 months of chronic THC administration (0.18–0.32 mg/kg, intramuscularly, twice daily). Duodenal tissue samples excised from chronic THC- (N=4) and vehicle (VEH)-treated (N=4) subjects at ∼5 months postinoculation showed lower viral load, increased duodenal integrin beta 7+(β7) CD4+ and CD8+ central memory T cells, and a significant preferential increase in Th2 cytokine expression. Gene array analysis identified six genes that were differentially expressed in intestinal samples of the THC/SIV animals when compared to those differentially expressed between VEH/SIV and uninfected controls. These genes were identified as having significant participation in (1) apoptosis, (2) cell survival, proliferation, and morphogenesis, and (3) energy and substrate metabolic processes. Additional analysis comparing the duodenal gene expression in THC/SIV vs. VEH/SIV animals identified 93 differentially expressed genes that participate in processes involved in muscle contraction, protein folding, cytoskeleton remodeling, cell adhesion, and cell signaling. Immunohistochemical staining showed attenuated apoptosis in epithelial crypt cells of THC/SIV subjects. Our results indicate that chronic THC administration modulated duodenal T cell populations, favored a pro-Th2 cytokine balance, and decreased intestinal apoptosis. These findings reveal novel mechanisms that may potentially contribute to cannabinoid-mediated disease modulation.
Get full access to this article
View all access options for this article.
References
1.
U.S. Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality: Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings. www.samhsa.gov/data/NSDUH/2k11Results/NSDUHresults2011.pdf2012.
2.
MolinaPE, WinsauerP, ZhangP, et al.: Cannabinoid administration attenuates the progression of simian immunodeficiency virus. AIDS Res Hum Retroviruses, 2011; 27:585–592.
3.
MolinaPE, AmedeeA, LeCapitaineNJ, et al.: Cannabinoid neuroimmune modulation of SIV disease. J Neuroimmune Pharmacol, 2011; 6:516–527.
4.
DandekarS: Pathogenesis of HIV in the gastrointestinal tract. Curr HIV/AIDS Rep, 2007; 4:10–15.
5.
GeorgeMD, ReayE, SankaranS, and DandekarS: Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol, 2005; 79:2709–2719.
6.
LingB, VeazeyRS, HartM, et al.: Early restoration of mucosal CD4 memory CCR5 T cells in the gut of SIV-infected rhesus predicts long term non-progression. AIDS, 2007; 21:2377–2385.
7.
ChunTW, NickleDC, JustementJS, et al.: Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy. J Infect Dis, 2008; 197:714–720.
8.
WrightK, RooneyN, FeeneyM, et al.: Differential expression of cannabinoid receptors in the human colon: Cannabinoids promote epithelial wound healing. Gastroenterology, 2005; 129:437–453.
9.
Kulkarni-NarlaA and BrownDR: Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res, 2000; 302:73–80.
10.
PertweeRG: Cannabinoids and the gastrointestinal tract. Gut, 2001; 48:859–867.
11.
IzzoAA, MascoloN, and CapassoF: The gastrointestinal pharmacology of cannabinoids. Curr Opin Pharmacol, 2001; 1:597–603.
12.
WrightKL, DuncanM, and SharkeyKA: Cannabinoid CB2 receptors in the gastrointestinal tract: A regulatory system in states of inflammation. Br J Pharmacol, 2008; 153:263–270.
13.
KimballES, SchneiderCR, WallaceNH, and HornbyPJ: Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol, 2006; 291:G364–G371.
14.
MassaF, MarsicanoG, HermannH, et al.: The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest, 2004; 113:1202–1209.
15.
StorrMA, KeenanCM, EmmerdingerD, et al.: Targeting endocannabinoid degradation protects against experimental colitis in mice: Involvement of CB1 and CB2 receptors. J Mol Med (Berl), 2008; 86:925–936.
16.
StorrMA, KeenanCM, ZhangH, PatelKD, MakrivannisA, and SharkeyKA: Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis, 2009; 15:1678–1685.
17.
SemanAL, PewenWF, FreshLF, MartinLN, and Murphey-CorbM: The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodeficiency virus in vitro is predictive of the rate of progression to AIDS in vivo. J Gen Virol, 2000; 81:2441–2449.
18.
BagbyGJ, StoltzDA, ZhangP, et al.: The effect of chronic binge ethanol consumption on the primary stage of SIV infection in rhesus macaques. Alcohol Clin Exp Res, 2003; 27:495–502.
19.
WinsauerPJ, MolinaPE, AmedeeAM, et al.: Tolerance to chronic delta-9-tetrahydrocannabinol (Δ[9]-THC) in rhesus macaques infected with simian immunodeficiency virus. Exp Clin Psychopharmacol, 2011; 19(2):154–172.
KimSH, SierraRA, McGeeDJ, and ZabaletaJ: Transcriptional profiling of gastric epithelial cells infected with wild type or arginase-deficient Helicobacter pylori. BMC Microbiol, 2012; 12:175.
22.
VenkatesanS, PetrovicA, LocatiM, KimYO, WeissmanD, and MurphyPM: A membrane-proximal basic domain and cysteine cluster in the C-terminal tail of CCR5 constitute a bipartite motif critical for cell surface expression. J Biol Chem, 2001; 276:40133–40145.
23.
BergerEA, MurphyPM, and FarberJM: Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu Rev Immunol, 1999; 17:657–700.
24.
LittmanDR: Chemokine receptors: Keys to AIDS pathogenesis?. Cell, 1998; 93(5):677–680.
25.
FukadaK, SobaoY, TomiyamaH, OkaS, and TakiguchiM: Functional expression of the chemokine receptor CCR5 on virus epitope-specific memory and effector CD8+ T cells. J Immunol, 2002; 168(5):2225–2232.
26.
EdingerAL, AmedeeA, MillerK, et al.: Differential utilization of CCR5 by macrophage and T cell tropic simian immunodeficiency virus strains. Proc Natl Acad Sci USA, 1997; 94:4005–4010.
27.
LiQ, DuanL, EstesJD, et al.: Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature, 2005; 434(7037):1148–1152.
28.
NewtonCA, KleinTW, and FriedmanH: Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun, 1994; 62:4015–4020.
29.
KleinTW, NewtonCA, NakachiN, and FriedmanH: Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol, 2000; 164:6461–6466.
30.
ZhuLX, SharmaS, StolinaM, et al.: Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol, 2000; 165:373–380.
31.
SmithSR, TerminelliC, and DenhardtG: Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther, 2000; 293:136–150.
32.
SmithSR, TerminelliC, and DenhardtG: Modulation of cytokine responses in Corynebacterium parvum-primed endotoxemic mice by centrally administered cannabinoid ligands. Eur J Pharmacol, 2001; 425:73–83.
33.
OuyangW, RanganathSH, WeindelK, et al.: Inhibition of Th1 development mediated by GATA-3 through an IL-4-independent mechanism. Immunity, 1998; 9:745–755.
34.
YuanM, KiertscherSM, ChengQ, ZoumalanR, TashkinDP, and RothMD: Delta 9-tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol, 2002; 133:124–131.
35.
KleinTW, NewtonC, LarsenK, et al.: The cannabinoid system and immune modulation. J Leukoc Biol, 2003; 74:486–496.
36.
KleinTW, NewtonC, LarsenK, et al.: Cannabinoid receptors and T helper cells. J Neuroimmunol, 2004; 147:91–94.
37.
CecchinatoV and FranchiniG: Th17 cells in pathogenic simian immunodeficiency virus infection of macaques. Curr Opin HIV AIDS, 2010; 5(2):141–145.
38.
VinuesaCG: HIV and T follicular helper cells: A dangerous relationship. J Clin Invest, 2012; 122:3059–3062.
39.
MontanerLJ, DoyleAG, CollinM, et al.: Interleukin 13 inhibits human immunodeficiency virus type 1 production in primary blood-derived human macrophages in vitro. J Exp Med, 1993; 178:743–747.
40.
StorrM, EmmerdingerD, DiegelmannJ, et al.: The role of fatty acid hydrolase gene variants in inflammatory bowel disease. Aliment Pharmacol Ther, 2009; 29:542–551.
41.
CecchinatoV, TrindadeCJ, LaurenceA, et al.: Altered balance between Th17 and Th1 cells at mucosal sites predicts AIDS progression in simian immunodeficiency virus-infected macaques. Mucosal Immunol, 2008; 1:279–288.
42.
Hartigan-O'ConnorDJ, HiraoLA, McCuneJM, and DandekarS: Th17 cells and regulatory T cells in elite control over HIV and SIV. Curr Opin HIV AIDS, 2011; 6:221–227.
43.
HiraoLA, HokeyDA, MorrowMP, Jure-KunkelMN, and WeinerDB: Immune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challenge. PLoS One, 2011; 6:e24250.
44.
XuH, WangX, LiuDX, Moroney-RasmussenT, LacknerAA, and VeazeyRS: IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques. Mucosal Immunol 201;5:658–669.
45.
De FilippisD, EspositoG, CirilloC, et al.: Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. PLoS One, 2011; 6:e28159.
46.
BrenchleyJM, PriceDA, SchackerTW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med, 2006; 12:1365–1371.
47.
ZoppiS, MadrigalJL, Perez-NievasBG, et al.: Endogenous cannabinoid system regulates intestinal barrier function in vivo through cannabinoid type 1 receptor activation. Am J Physiol Gastrointest Liver Physiol, 2012; 302:G565–G571.
48.
RamirezSH, HaskoJ, SkubaA, et al.: Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci, 2012; 32:4004–4016.
